Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)

Figure 4

Changes from the baseline value for serum creatinine (Cr), estimated glomerular filtration rate (eGFR), serum cystatin C, serum K, serum uric acid (UA), glycoalbumin (GA), serum high density lipoprotein cholesterol (HDL), serum low density lipoprotein cholesterol (LDL-C), serum triglyceride (TG), plasma active renin concentration (ARC), and plasma aldosterone during 12 months of treatment with olmesartan monotherapy (open circles) or combination therapy with olmesartan and azelnidipine (closed circles). ^†𝑃<.05 versus the olmesartan monotherapy.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)